APPROVED FOR USE

in patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression as consolidation treatment post auto-HSCT.1

Full Prescribing Information

Full Prescribing Information

Request visit

Request visit from a representative (HCPs only)

ADCETRIS Patient Brochure

ADCETRIS Patient Brochure


Indication

ADCETRIS is indicated for use in patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression as consolidation treatment after stem cell transplantation.

What is the Most Important Serious Safety Information I Should Know About ADCETRIS® (brentuximab vedotin) for injection?

What are the Other Possible Serious Side Effects of ADCETRIS?

What Were the Most Common Side Effects in Clinical Trials?

ADCETRIS was studied by itself in 160 patients in two clinical trials in patients with relapsed classical HL and relapsed sALCL. Across both trials, the most common side effects were a low number of white blood cells, tingling or numbness in the hands or feet, feeling tired, nausea, a low number of red blood cells, an infection in the upper respiratory tract, diarrhea, fever, rash, a low number of platelets (which help the blood clot), cough, and vomiting.

ADCETRIS was studied in a trial with 329 patients with classical HL at high risk of relapse or progression after stem cell transplantation. The most common side effects in patients who received ADCETRIS (167 patients), were a low number of white blood cells, tingling or numbness in the hands or feet, a low number of platelets (which help the blood clot), a low number of red blood cells, an infection in the upper respiratory tract, feeling tired, trouble moving the hands or feet, nausea, cough, and diarrhea.

What Should I Tell My Doctor Before I Start Treatment with ADCETRIS® (brentuximab vedotin) for injection?

Contact Your Doctor if You Experience Any of the Following: